Tracking API Growth - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tracking API Growth
Growth in emerging markets and across the generic-drug sector shifts the global demand and supply of active pharmaceutical ingredients.

Pharmaceutical Technology
Volume 34, Issue 1, pp. 46-49

API production

The emergence of China and India as low-cost production centers for APIs, combined with rising domestic demand in those countries, is shifting the balance of API production on a global level from Western Europe to Asia. China has become the largest API producer globally, holding 9.3% of the global merchant market (both innovator and generic APIs) in 2008 and 37.8% of the merchant market for generic APIs. Italy now ranks second, with a 10.4% share on the global merchant market for both innovator and generic APIs and a 16.7% piece of the global merchant market for generic APIs. Japan ranks third, which includes primarily innovator APIs. India ranks fourth in global API production with 7.4% of the global merchant market for both innovator and generic APIs in 2008, but ranks third in generic API production, with a 13.4% share, according to CPA.

Although India and China have increased their share of global API production, Western Europe remains the largest API-producing region in the world. Western Europe accounted for 38.9% of global API production (innovator and generic) in 2008, although this level is down from a 44.3% share in 2004, according to CPA. The Asia-Pacific region ranks a close second, with a 38.4% share of global API production (both innovator and generic), but holds a majority share of global generic API production with a 54.8% share in 2008. Italy has retained its historical position as the number one exporter of APIs to the US. Imports account for approximately 80% of total US generic API consumption, according to CPA, and of this amount, Italy accounts for 37% of US imports. China ranks second with 18%, followed by Spain and Portugal at 17%, and India at 8%.

APIs under development

Despite shifts to offshore markets in commercial APIs, research and development (R&D) by the large US-based multinationals is still largely based in the US. Domestic R&D spending accounted for $36.2 billion, or 75.5%, of R&D expenditures for human pharmaceuticals, and R&D spending aboard was $11 billion, or 23%, bringing total R&D spending on human pharmaceuticals to $47.2 billion in 2007, according to the Pharmaceutical Research and Manufacturers of America (PhRMA). Domestic R&D is defined as R&D in the US by PhRMA member companies. R&D abroad is R&D conducted outside the US by US-owned PhRMA companies and R&D conducted abroad by the US divisions of foreign-owned PhRMA companies. R&D spending performed abroad by the foreign divisions of foreign-owned divisions of foreign-owned PhRMA member companies are excluded. R&D spending (both domestic and abroad) on veterinary pharmaceuticals accounted for $718.4 million, or 1.5% of R&D spending, bringing total R&D spending by PhRMA member companies to $47.9 billion in 2007; it was $50.3 billion in 2008.

Of the $47.9 billion total in 2007, spending was greatest in Phase III and in prehuman/preclinical development, which respectively accounted for 28.5% and 27.3% of total R&D spending by PhRMA member companies. R&D spending for the rest of development broke down as follows: Phase I (7.4%), Phase II (13.0%), Approval (5.0%), Phase IV (13.4%), and uncategorized (5.2%). The drugs under development also were largely developed internally by the large companies. Self-originated compounds accounted for $27.1 billion, or 74.1%, of domestic R&D spending by PhRMA member companies in 2007. In-licensed compounds accounted for $63.3 billion, or 17.2%, and 8.7% of the drugs were uncategorized. Overall, there were approximately 2900 drugs in clinical development or awaiting review by the US Food and Drug Administration in 2009.

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here